Skip to content

Scilex Holding Company SCLX Free cash flow margin

Free cash flow margin at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
41.4%+10.4pp
Viatris logo
ViatrisVTRS
12.3%-1.0pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-75%-30.5pp
Opko Health logo
Opko HealthOPK
-30%+0.1pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-75.1%+10.7pp
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-463%+2,860pp

Other financials

Income statement

See full
Revenue$8.6M+72.1%
Gross profit$4.2M+15.1%
Operating income-$32.2M-15.3%
Net income-$45.7M-75.0%
EPS (diluted)-$6.28-178%

Balance sheet

See full
Cash & equivalents$3.4M-42.2%
Total debt$95.4M+130%
Total equity-$249.2M-17.8%
Total assets$293.6M+272%

Cash flow

See full
Operating cash flow-$1.1M-118%
CapEx$33.3K
Free cash flow$920.8K-63.7%

Valuation

See full
Market cap$54.86M+88.7%
Enterprise value$146.86M+120%
P/S1.6×+1.0×

Profitability

See full
Gross margin59.7%-12.3pp
Operating margin-1,034.4%-1,313pp
Net margin-1,162.4%-1,359pp

Returns & leverage

See full
Return on equity170.9%
Debt / equity0.3×
Current ratio0.1×0.0×

Where this comes from

Calculated from Scilex Holding Company’s reported figures.

Based on trailing twelve months.

The official record: Scilex Holding Company’s 10-Q, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scilex Holding Company's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scilex Holding Company's free cash flow margin?
Scilex Holding Company (SCLX) reported free cash flow margin of 12.2% in Q4 2025.
What is the long-term trend for Scilex Holding Company's free cash flow margin?
Over 3 years (2020 to 2025), Scilex Holding Company's free cash flow margin has grown at a -55.0% compound annual growth rate (CAGR), from -133.6% to 12.2%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.